GlassScriptPhysician profile
Carolyn Hendricks
NPI 1205896776
$640.59
in general payments reported to CMS, 2019-2025
16 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.92 · 2023: $134 · 2024: $263 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $628.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $113.42 | 2023-2025 | Enhertu, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $105.12 | 2024 | Opdivo, Opdualag |
| Glaxosmithkline, LLC. | $83.91 | 2024-2025 | Zejula, Jemperli, Ojjaara |
| Merck Sharp & Dohme LLC | $77.71 | 2023-2025 | Keytruda, Lynparza |
| Pfizer INC. | $58.81 | 2025 | |
| Incyte Corporation | $55.55 | 2023-2024 | Jakafi |
| Genzyme Corporation | $45.18 | 2024 | |
| Array Biopharma INC | $22.25 | 2025 | Braftovi, Lorbrena |
| Janssen Biotech, INC. | $19.51 | 2023 | Erleada |
| Coherus Oncology, INC. | $18.57 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $14.41 | 2024 | Calquence |
| Deciphera Pharmaceuticals INC. | $14.23 | 2025 | Tgct, Qinlock |
| Gilead Sciences, INC. | $11.92 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolyn Hendricks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.